Cargando…

Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that is prone to recurrence and metastasis. Because of the lack of expression of estrogen receptor (ER) and progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) in TNBC, treatment methods a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jian, Dan, Li, Xue-Mei, Dai, Nan, Liang, Dan-Dan, Zhang, Gang, Mao, Cheng-Yi, Wang, Dong, Song, Guan-Bin, Li, Meng-Xia, Luo, Hao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020940/ https://www.ncbi.nlm.nih.gov/pubmed/35463096 http://dx.doi.org/10.1155/2022/6048017

Ejemplares similares

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer
por: Jang, Na Young, et al.
Publicado: (2015)

Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells
por: Zhao, Hui, et al.
Publicado: (2018)

Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
por: Ha, Dong-Hyeon, et al.
Publicado: (2020)

The love of monkeys and apes
por: Freeman, Dan
Publicado: (1977)

Durable Disease-free Survival in a Patient with Metastatic Triple-negative Breast Cancer Treated with Olaparib Monotherapy
por: Wang, Xue, et al.
Publicado: (2022)

Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer
por: Lee, Jung-Min, et al.
Publicado: (2017)

Effect of Oxaliplatin, Olaparib and LY294002 in Combination on Triple-Negative Breast Cancer Cells
por: Andreidesz, Kitti, et al.
Publicado: (2021)

Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice
por: Chen, Li-Mei, et al.
Publicado: (2022)

miR-27-3p Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to the Antitumor Agent Olaparib by Targeting PSEN-1, the Catalytic Subunit of Γ-Secretase
por: Zhao, Meng, et al.
Publicado: (2021)

Analysis of Adaptive Olaparib Resistance Effects on Cisplatin Sensitivity in Triple Negative Breast Cancer Cells
por: Gajan, Ambikai, et al.
Publicado: (2021)

Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation
por: Li, Xiaofen, et al.
Publicado: (2021)

Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells
por: Mani, Chinnadurai, et al.
Publicado: (2019)

PRMT1 Confers Resistance to Olaparib via Modulating MYC Signaling in Triple-Negative Breast Cancer
por: Hsu, Wen-Jing, et al.
Publicado: (2021)

Cost-Effectiveness of Genomic Test-Directed Olaparib for Metastatic Castration-Resistant Prostate Cancer
por: Su, Dan, et al.
Publicado: (2021)

Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report
por: Li, Mao, et al.
Publicado: (2018)

Resveratrol Mediates the Apoptosis of Triple Negative Breast Cancer Cells by Reducing POLD1 Expression
por: Liang, Zhi-Jie, et al.
Publicado: (2021)

Apes reciprocate food positively and negatively
por: Benozio, Avi, et al.
Publicado: (2023)

Mental distress, quality of life and physical symptoms in Chinese women with ovarian cancer receiving olaparib treatment during the COVID-19 pandemic
por: Mao, Wei, et al.
Publicado: (2022)

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer
por: Mazzucchelli, S., et al.
Publicado: (2017)

Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial
por: Schettini, Francesco, et al.
Publicado: (2021)

Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer
por: Li, Haonan, et al.
Publicado: (2020)

Radiogenomic analysis reveals tumor heterogeneity of triple-negative breast cancer
por: Jiang, Lin, et al.
Publicado: (2022)

Learning from communication versus observation in great apes
por: Marno, Hanna, et al.
Publicado: (2022)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple‐negative breast cancer
por: Corrales‐Sánchez, Verónica, et al.
Publicado: (2020)

A Screened GPR1 Peptide Exerts Antitumor Effects on Triple-Negative Breast Cancer
por: Huang, Chen, et al.
Publicado: (2020)

From APE to APE-100: present and future of the APE project
por: Bacilieri, P, et al.
Publicado: (1988)

BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression
por: Li, Yu, et al.
Publicado: (2021)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

Identification of a novel potential antitumor activity of gossypol as an APE1/Ref-1 inhibitor
por: Qian, Chengyuan, et al.
Publicado: (2014)

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade
por: Luo, Hao, et al.
Publicado: (2022)

XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib
por: Ali, Reem, et al.
Publicado: (2020)

Combining Carbon-Ion Irradiation and PARP Inhibitor, Olaparib Efficiently Kills BRCA1-Mutated Triple-Negative Breast Cancer Cells
por: Kawanishi, Miki, et al.
Publicado: (2022)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Inhibiting the redox function of APE1 suppresses cervical cancer metastasis via disengagement of ZEB1 from E-cadherin in EMT
por: Li, Qing, et al.
Publicado: (2021)

ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma
por: Gu, Zhuoyu, et al.
Publicado: (2020)

Apes
por: Lowenstine, Linda J., et al.
Publicado: (2018)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Dezocine, An Opioid Analgesic, Exerts Antitumor Effects in Triple-Negative Breast Cancer by Targeting Nicotinamide Phosphoribosyltransferase
por: Xue, Chenyang, et al.
Publicado: (2021)

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
por: Dufour, Robin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1vo2s2v7flquestln68gdgiuug